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Abstract
We conducted a genome-wide association study for androgenic alopecia in 1,125 men and
identified a newly associated locus at chromosome 20p11.22, confirmed in three independent
cohorts (n = 1,650; OR = 1.60, P = 1.1 × 10−14 for rs1160312). The one man in seven who harbors
risk alleles at both 20p11.22 and AR (encoding the androgen receptor) has a sevenfold-increased
odds of androgenic alopecia (OR = 7.12, P = 3.7 × 10−15).
Androgenic alopecia is a common disorder affecting 40% of adult men and women1. Men
and women with hair loss experience negative body-image perceptions2. Moreover, the
mechanisms involved in androgenic alopecia may influence common medical disorders,
such as coronary heart disease and metabolic syndrome3. Underscoring the social
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implications of baldness, global annual sales of a medical therapy for male-pattern baldness
recently surpassed $405 million (Merck Financial Disclosures, Fourth Quarter 2007).
Androgenic alopecia is a highly heritable condition, with heritability estimates of over
80%4. Genetic variants in, or in proximity to, the AR (androgen receptor) gene have been
previously associated with male-pattern baldness5-9. However, as the inheritance pattern of
this trait seems to be polygenic, we undertook a two-stage genome-wide association (GWA)
study for androgenic alopecia.
We carried out an extreme discordant case-control GWA scan for androgenic alopecia
nested within the CoLaus population-based study in Lausanne, Switzerland10. A total of
578 male individuals with early-onset alopecia were compared with 547 male control
individuals without alopecia (Supplementary Methods online). In the second stage, we
sought replication in independent samples from the UK, Iceland and The Netherlands. The
UK cohort comprised 453 men (176 affected individuals) from a population-based sample of
British twins; 1,308 women (95 affected individuals) from this sample were also assessed
for hair loss. The Dutch cohort comprised 463 men (147 affected individuals) previously
diagnosed with prostate cancer and also assessed for androgenic alopecia. The Icelandic
study included 734 Icelandic men (536 affected individuals) and 878 Icelandic women (397
affected individuals). The overall sample size thus comprised 4,961 individuals.
The GWA study (Supplementary Fig. 1 online) was done using the Affymetrix GeneChip
Human Mapping 500K array in the CoLaus cohort. All SNPs from this GWA study with a P
value ≤ 10−5 were from two loci (Supplementary Fig. 2 online). We confirmed the
importance of the previously described AR gene5-9 (OR for lead SNP rs6625163[A] = 3.30
(2.31-4.71), P = 5.0 × 10−11). We also located a new susceptibility locus on chromosome
20p11.22 (OR = 1.79 (1.49-2.15), P = 3.2 × 10−10 for rs1160312[A] and OR = 1.80
(1.49-2.16), P = 3.5 × 10−10 for rs913063[T]; the r2 between rs1160312 and rs913063 was
1.0; Table 1). These SNPs are located over 350 kb distant to the nearest annotated gene,
PAX1.
This same risk allele at rs1160312, rs1160312[A], was associated with an increased risk of
androgenic alopecia in the TwinsUK cohort (OR = 1.68 (1.22-2.33), P = 2.0 × 10−3), hair
loss in men in the Icelandic cohort (OR = 1.41 (1.10-1.79), P = 6.1 × 10−3) and androgenic
alopecia in the Dutch cohort (OR = 1.40 (1.06-1.85), P = 0.018). In a combined analysis of
all male cases and controls, the risk allele was strongly associated with hair loss (OR = 1.60
(1.42-1.80), P = 1.1 × 10−14). In addition, the same risk allele was associated with hair loss
in women (OR = 1.24 (1.05-1.47), P = 0.012) for combined data from Icelandic and
TwinsUK women (OR = 1.29 (1.05-1.57), P = 0.01 for Icelandic women; OR = 1.13
(0.82-1.56), P = 0.45 for women from the TwinsUK cohort).
We found that 14% of men harbored at least one risk allele at both 20p11.22 and the AR
gene and that this was associated with a markedly increased risk of androgenic alopecia (OR
= 7.12 (4.34-11.68), P = 3.7 × 10−15) in the CoLaus cohort. We observed no significant
statistical interaction between the two loci. The variance in androgenic alopecia explained
by the presence of at least one risk allele at both loci was 13.7%. Using all men from the
population-based CoLaus study who did not meet case or control definitions and who were
not included in the GWA scan (n = 940), we found that the ability of these two risk alleles to
exclude the development of androgenic alopecia was high, but lacked specificity (negative
predictive value = 96.5%, positive predictive value = 12.2%, sensitivity = 98.2%, specificity
= 6.6%).
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The rs1160312 SNP lies between PAX1 and FOXA2 on chromosome 20. It is not
immediately clear how this gene might affect androgenic alopecia. Although rs1160312 is
over 350 kb away from both genes, it remains possible that this SNP (or another variant in
linkage disequilibrium with it) may influence the expression of either transcript through
long-range control, as has been demonstrated for other genes involved in development11.
How these variants affect disease outcomes deserves further investigation.
The fact that, despite a relatively small number of subjects, rs1160312 had a genome-wide
significant association with androgenic alopecia in the discovery cohort alone and several
other SNPs within the LD block bearing rs1160312 were associated with androgenic
alopecia (Fig. 1) reflects the strength of the extreme discordant age-based case-control
definitions. The phenotype from the Icelandic and the female TwinsUK cohorts was derived
from self-reported hair loss, without the use of matching diagrams. Although this phenotype
definition is less precise than that derived using diagram-matching techniques, which have
been previously validated12, the association for males was replicated in Iceland and the
results for females are consistent between the cohorts. However, it is necessary to
investigate the association for female hair loss in larger and carefully phenotyped cohorts.
Even though the definition of hair loss and the method of sampling differed between the four
study groups, the fact that the association was observed in all groups underscores the
generalizability of our findings to other European populations. We also note that, as in any
GWA study, the identified variant is likely to be in linkage disequilibrium with the causal
SNP.
These results may have clinical significance. Androgenic alopecia is a disease of
considerable social concern and the scalp is one of the few areas that are directly accessible
by liposome–DNA mixtures13; this method has been demonstrated to result in hair-follicle
transfection14. Therefore, if a variant at 20p11.22 influences expression of a transcript, such
as PAX1 or FOXA2, then manipulation of this pathway may lead to a target for gene
therapy. However, demonstration of an influence of the chromosome 20p11.22 locus on
transcription of either gene requires further investigation. The relatively high prevalence and
magnitude of risk attributed to the risk alleles at both AR and 20p11.22 loci suggests that
these markers may assist in the identification of groups of men at high risk for androgenic
alopecia, and the absence of these risk alleles can be helpful in excluding its development.
In summary, we report a replicated GWA study for androgenic alopecia providing evidence
from four distinct European populations for a newly associated locus that influences a
common disorder of social importance. The risk alleles at this newly identified locus and AR
are common in Europeans and impart a relatively large risk for androgenic alopecia. Given
the feasibility of gene therapy in human follicles, our results may point to an intriguing new
potential target for the treatment of hair loss.
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Figure 1.
Association between SNPs near chromosome 20p11.22 and androgenic alopecia. (a) −log (P
value) measures for association between SNPs and chromosomal position. (b)
Recombination hot spots (HapMap CEPH population, NCBI build 36). (c) Linkage
disequilibrium in GOLD heat map Haploview 4.0 color scheme, CEPH population. The x
axis represents genomic position in Mb (a) and in kb (b,c). All P values are derived from the
CoLaus cohort, except that for the lead SNP, rs11603132, which is derived from the
combined P value from the CoLaus, TwinsUK, Icelandic and Dutch cohorts.
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